Financials
Financial year 2025
Revenue
€ 22.9 million
▲ 7% vs 2023
Profit
Healthy€ 1.6 million
▼ 79% vs 2023
Debts
Low€ 80.8 million
▼ 13% vs 2023
ECUPHAR from Oostkamp, company number BE0476255350, closed financial year 2025 with a result of € 1.6 million after tax. For that financial year ECUPHAR recorded revenue of € 22.9 million and equity of € 83.3 million. Compared with financial year 2023, the result moved from € 7.7 million to € 1.6 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
What happened at ECUPHAR?
What happened at ECUPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jenny Winter stepped down as director. NBB
- Christopher Brewster stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 1.6 million (▼ 79% vs 2023). Source: NBB ↗
- Jenny Winter became a director. NBB
- Christopher Brewster became a director. NBB
- New establishment in Oostkamp. KBO
- Start of the company according to the CBE. KBO
In short
From € 342,703 profit in 2021 to € 1.6 million profit in 2025.
Paid € 15,780 in corporate taxes since 2021.
Best year ever: 2023, with € 7.7 million profit.
Paid out € 26.5 million in dividends to the owners in total.
A new publication or filing at ECUPHAR? We notify you, reason included.
Follow ECUPHARNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of Ornis, 100% of ECUPHAR VETERINARY PRODUCTS, 100% of ECUPHAR VETERINARIA SLU, 100% of EURACON PHARMA CONSULTING UND TRADING, 100% of Ecuphar GmbH and 100% of ECUPHAR ITALIA itself.
Directors
According to the 2025 annual accounts
Jenny Winter
Director
since 2024 · until 2029
Christopher Brewster
Director
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Legeweg 157 box I
8020 Oostkamp
Legeweg 157 box i
8020 Oostkamp
Active since 19 April 2002
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
DIRAME ORTHO
€ 335,440 gross margin · 2025
EHC Invest
€ 82,089 revenue · 2025
Jimber
€ 757,960 gross margin · 2025
Vetdis Holding
€ 120,000 revenue · 2025
LAUNCHPAD EUROPE
€ 10,335 gross margin · 2025
+6 more
Details
- Company number
- 0476.255.350
- VAT number
- BE 0476.255.350
- Registered office
- Legeweg 157 bus I, 8020 Oostkamp
- Names & denominations
- ECUPHAR · Cardon Pharmaceuticals
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 December 2001
- Peppol
- Active · Active since 5 Jun 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Public relationsbureaus
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie